Warning letter
Libi Labs, Inc.: warning letter of Mar 13, 2014
FDA warning letter 396439 · Florida District Office
Key facts
| Reference number | 396439 |
|---|---|
| Company | Libi Labs, Inc. |
| Subject | CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Mar 13, 2014 |
| Posted date | Apr 1, 2014 |
| Issuing office | Florida District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111, 111.210, 111.70(b), 111.70(c)(1), 111.75(a)(2)(ii), 111.205(a), 111.210(h), 111.210(h)(3), 111.75(a)(1)(i), 111.75(a)(1)(ii) |
| Inspection city | Largo |
| Inspection ZIP | 33777 |
| Inspection start date | Mar 25, 2013 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: